Opiddiction Goes Global Overview
Opiddiction Goes Global
As many states enact loid Aaws that set time or dosage limits on prescription or dispensation of controlled substances including opioids, the demand for legally sold opioids is declining slightly in the United States (CDC, n.d.). The illegal market, however, is booming.
After legal actions were taken against the tobacco industry in the United States, the industry responded by increasing international marketing efforts. “Big Pharma” is now doing the same (Ryan, Girion, & Glover, 2016).
It is estimated that between 5 and 8 billion people outside the United States do not have access to pain medications, which represents an enormous growth opportunity for companies like Purdue, producer and distributor of oxycodone. Remember: when Purdue introduced oxycodone in the United States, they claimed it was nonaddictive.
Using the materials in this unit, some of which are linked in Resources, complete the following:
- Provide three examples that argue in favor of making drugs like oxycodone more available to people in severe pain globally.
- Present three examples that argue for tighter international regulations on the marketing and sales of these drugs.
- Use APA style and formatting to cite your research.
Please choose posts that have had few responses thus far. Respond with all of the following:
- Engage your peer. Tell him or her specifically why you chose to respond to the post.
- Seek clarification. Talk about what is unclear. Ask questions. Offer suggestions.
- Include personal examples or work experiences that add perspective to your reply.
- Be a practitioner/scholar. In addition to your personal or work experience, include one academic reference in your response. Use APA style and formatting appropriate to the type of reference you provide.
Refer to the Faculty Expectations for Response Guidelines.
Centers for Disease Control and Prevention. (n.d.). Prescription drugs. Retrieved from https://www.cdc.gov/phlp/publications/topic/prescription.html
Ryan, H., Girion, L., & Glover, S. (2016, Dec. 18). OxyContin goes global —“We’re only just getting started” [Blog post]. Retrieved from http://www.latimes.com/projects/la-me-oxycontin-part3/